CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.

doi:10.3324/haematol.2016.151910

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.

Haematologica - 1 Mar 2017

Mannelli Francesco, Ponziani Vanessa, Bencini Sara, Bonetti Maria Ida, Benelli Matteo, Cutini Ilaria, Gianfaldoni Giacomo, Scappini Barbara, Pancani Fabiana, Piccini Matteo, Rondelli Tommaso, Caporale Roberto, Gelli Anna Maria Grazia, Peruzzi Benedetta, Chiarini Marco, Borlenghi Erika, Spinelli Orietta, Giupponi Damiano, Zanghì Pamela, Bassan Renato, Rambaldi Alessandro, Rossi Giuseppe, Bosi Alberto

Abstract excerpt

Mutations in CCAAT/enhancer binding protein α (CEBPA) occur in 5-10% of cases of acute myeloid leukemia. CEBPA-double-mutated cases usually bear biallelic N- and C-terminal mutations and are associated with a favorable clinical outcome. Identification of CEBPA mutants is challenging because of the variety of mutations, intrinsic characteristics of the gene and technical issues. Several screening methods...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CCAAT-Enhancer-Binding Protein-alpha

Share to Cytogenetic Analysis

Share to Immunophenotyping

Share to Kaplan-Meier Estimate

Share to Leukemia, Myeloid, Acute

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 28250006
DOI: 10.3324/haematol.2016.151910
PMCID: PMC5394975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.PMID 28250006Read ↗

Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.Semantic proximity Read ↗

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Semantic proximity Read ↗

Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndromeSemantic proximity Read ↗

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.Semantic proximity Read ↗

Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significanceSemantic proximity Read ↗

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.Semantic proximity Read ↗

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future DirectionsSemantic proximity Read ↗

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.Semantic proximity Read ↗

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical OutcomeSemantic proximity Read ↗

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPASemantic proximity Read ↗

Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.Semantic proximity Read ↗

CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.